Identifying biomarkers for pancreatic cancer
Official title: BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?
Run by Herlev Hospital · NCT03311776 · Data updated 2026-11-12
This study is trying to find new markers in blood samples from people with pancreatic cancer to help doctors detect the disease earlier and improve treatment results.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Herlev Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Herlev) |
| Status | Recruiting |
| Started | July 3, 2008 |
| Main results expected | July 2, 2035 |
| Study ends | July 2, 2035 |
| Registry record updated | March 1, 2023 |
| Trial ID | NCT03311776 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with histologically verified pancreatic cancer or those suspected of having it based on clinical and radiological characteristics.
✕Probably not a fit
Patients without a confirmed diagnosis of pancreatic cancer or those under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to discover diagnostic, prognostic, and predictive biomarkers for pancreatic cancer (PC) to enhance early detection and treatment outcomes. It involves the prospective collection of biological samples and clinical data from patients diagnosed with PC or suspected malignancy. Participants will provide blood samples before surgery or chemotherapy and during treatment, with follow-ups until disease progression. The goal is to improve the specificity and sensitivity of PC diagnosis and to monitor treatment effectiveness.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better treatment strategies for pancreatic cancer patients.
How similar studies have gone: Other studies have explored biomarkers in pancreatic cancer, but this specific approach to early detection and treatment monitoring is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Histologically verified PC (ductal adenocarcinoma) or ampullary adenocarcinoma in a resected specimen; or histopathological confirmation of carcinoma in patients not undergoing surgery in the setting of clinical and radiological characteristics which, together with the pathology, are consistent with a diagnosis of PC independently of stage Exclusion Criteria: • None
Where it's running
-
Herlev & Gentofte Hospital
Herlev, Denmark Recruiting
Study contacts
- Study coordinator: Julia Sidenius Johansen, MD, DMsc
- Email: Julia.Sidenius.Johansen@regionh.dk
- Phone: +45 38689241
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)
This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.